

After more than a century of active research, uric acid has gained the stage as of one of the most reliable candidates for the huge amount of residual cardio-metabolic risk.

The involvement of uric acid in the pathophysiology of hypertension, diabetes and metabolic syndrome, particularly at younger ages, supports the importance of the research in this area.

The interaction between genetics, biochemistry, epidemiology and lifestyle is the engine that has boosted the worldwide interest for uric acid and cardio-metabolic disease.

Now is time to move from academy to clinical practice since we urgently need a reliable tool to identify which patients deserve something more than theory and hypothesis.

The 4<sup>th</sup> edition of the Bologna meeting will be focused on the patient with the goal to discuss several burning topics:

- Are all the patients with elevated serum uric acid levels the same?
- What is the threshold level for "cardio-metabolic" hyperuricemia?
- How to identify the patients at risk of cardio-metabolic disease?
- What about in children and adolescents?
- What are the differences with cardiovascular complicated gout?
- What are the preventive/therapeutic strategies?
- What is the role of ULT?
- What advantages/harm of the use of non-ULT drugs affecting uric acid?
- What is the current position of Guidelines?



# URIC ACID AND CARDIOMETABOLIC DISEASE: FROM BENCH TO BEDSIDE

### WITH THE ENDORSEMENT OF:













### PRESIDENT OF THE MEETING:

### Claudio Borghi

Department of Medical and Surgical Sciences (DIMEC)
Department of Internal Medicine

Alma Mater Studiorum University of Bologna

St. Orsola-Malpighi University Hospital (Bologna, Italy)

### **CO-ORGANIZER:**

### Richard J. Johnson

Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus (Aurora-CO, USA)

### SCIENTIFIC SECRETARIAT:

### Arrigo F.G. Cicero

Alma Mater Studiorum University of Bologna (Bologna, Italy)

### **Agostino Virdis**

University of Pisa (Pisa, Italy)

## ORGANIZING SECRETARIAT AND PROVIDER FOR ITALIAN CME ACCREDITATION:

### I&C s.r.l.

Via Andrea Costa, 202/6, 40134 Bologna (Italy) Tel.: +39 051 6144004 - Fax: +39 051 6142772

E-mail: stefania.parolari@iec-srl.it - roberta.loggini@iec-srl.it

Website: www.iec-srl.it

### WITH AN UNRESTRICTED GRANT BY:

### Fondazione Internazionale Menarini

Centro Direzionale Milanofiori

20089 Rozzano (Milan, Italy) Edificio L – Strada 6 Phone: +39 02 55308110 - Fax: +39 02 55305739

E-mail: milan@fondazione-menarini.it Website: www.fondazione-menarini.it



# Tuesday, November 13<sup>TH</sup>, 2018 – Morning Salone del Podestà – Palazzo Re Enzo

09.00 a.m. Introduction to the meeting objectives **C. Borghi** (Bologna, IT)

# Session I – The cardio-metabolic burden in patients with gout

Chairpersons:	E. Agabiti Rosei (Brescia, IT) T. Gibson (London, UK)
09.20 a.m.	<b>F. M. Galassi</b> (Adelaide, AU) Uric acid and gout: tales from the Ancient World
09.40 a.m.	<b>L. Punzi</b> (Padua, IT) The cardio-metabolic involvement in gout. The position of guidelines
10.00 a.m.	<ul><li>D. Rothenbacher (Ulm, DE)</li><li>How can we quantify the cardio-metabolic risk in patients with gout?</li><li>An epidemiological perspective</li></ul>
10.20 a.m.	M. Andrés (Alicante, ES) The management of cardio-metabolic risk in patients with gout
10.40 a.m.	M. M. Givertz (Boston-MA,US) Treating gout in patients with cardiovascular disease
11.00 a.m.	General discussion
11.30 a.m.	Coffee break
	Main Lecture
12.00 p.m.	Introduction:  E. Ambrosioni (Bologna, IT), M. H. Alderman (New York-NY, US)
	<b>R. J. Johnson</b> (Aurora-CO, US) From uric acid to cardio-metabolic disease: can we identify the patients at risk?
01.00 p.m.	Lunch


# Tuesday, November 13<sup>™</sup>, 2018 – Afternoon Salone del Podestà - Palazzo Re Enzo

# Session II – Update on the clinical evidence: uric acid and cardiovascular disease

Chairpersons:	P. Palatini (Padua, IT) J. Redon (Valencia, ES)
02.00 p.m.	A. Virdis (Pisa, IT) Uric acid and blood pressure
02.20 p.m.	<b>S. G. Wannamethee</b> (London, UK) Uric acid, left ventricular function and heart failure
02.40 p.m.	G. Ambrosio (Perugia, IT) Uric acid and coronary artery disease
03.00 p.m.	K. Tsioufis (Athens, GR) Uric acid and atrial fibrillation
03.20 p.m.	General discussion
03.40 p.m.	Coffee break

# Session III – Update on the clinical evidence: uric acid, metabolic and renal disease

Chairpersons:	M. Burnier (Lausanne, CH) C. Borghi (Bologna, IT)
04.10 p.m.	<b>D. H. Kang</b> (Seoul, KR) Uric acid and new-onset metabolic syndrome
04.30 p.m.	M. Kuwabara (Tokyo, JP) The interaction between uric acid and lipid profile
04.50 p.m.	R. Pontremoli (Genoa, IT) Uric acid and renal dysfunction: what is the egg?
05.10 p.m.	R. Cifkova (Prague, CZ) Uric acid, pregnancy and cardio-renal disease
05.30 p.m.	General discussion
06.00 p.m.	Conclusion and end of the sessions



# Wednesday, November 14<sup>™</sup>, 2018 – Morning Salone del Podestà – Palazzo Re Enzo

08.30 a.m.	Introduction to the meeting objectives
00.30 d.III.	C. Borghi (Bologna, IT)

# Session IV – Quantification of Cardio-Metabolic Risk in Patients with Hyperuricemia

Chairpersons:	G. Mancia (Milan, IT) A. J. Manolis (Athens, GR)
09.00 a.m.	C. Ferri (L'Aquila, IT) Is drug-induced hyperuricemia a cardio-metabolic risk factor?
09.20 a.m.	<b>T. R. Merriman</b> (Dunedin, NZ) Is genetic approach the right solution?
09.40 a.m.	J. Dawson (Glasgow, UK) Is genetic profile useful for clinical practice?
10.00 a.m.	M. Burnier (Lausanne, CH) Is the measure of xantino-oxidase a reliable tool?
10.20 a.m.	L. Scheepers, (Gothenburg, SE) Is it reasonable to consider a functional index?
10.40 a.m.	General discussion
11.00 a.m.	Coffee break

# Session V - Prevention of Cardio-Metabolic risk in Patients with Hyperuricemia

_	
Chairpersons:	M. L. Muiesan (Brescia, IT) K. Narkiewicz (Gdansk, PL)
11.30 a.m.	<b>E. Lurbe</b> (Valencia, ES) Age-dependent prevention of hyperuricemia: the earlier is the better?
11.50 a.m.	<b>D. I. Feig</b> (Birmingham-AL, US) The role of fructose consumption and dietary approach
12.10 a.m.	<b>G. Grassi</b> (Milan, IT) The management of additional risk factors in patients with hyperuricemia
12.30 p.m.	G. Desideri (L'Aquila, IT) Is the determination of serum uric acid enough?
12.50 p.m.	General discussion
01.00 p.m.	Lunch

# Wednesday, November 14<sup>™</sup>, 2018 – Afternoon Salone del Podestà – Palazzo Re Enzo

## Session VI – Hyperuricemia and cardio-metabolic risk: who is to treat?

Chairpersons:	S. Taddei (Pisa, IT) A. J. Manolis (Athens, GR)
02.00 p.m.	<ul><li>P.M. Nilsson (Malmo, SE)</li><li>SGLT-2 inhibitors and control of uric acid: mechanism and potential advantages</li></ul>
02.20 p.m.	<b>J. George</b> (Dundee, UK) Urate lowering drugs and prevention of cardiometabolic disease: the evidence
02.40 p.m.	<b>S. Masi</b> (Pisa, IT) Recent evidence in cardiorenal protection with Urate Lowering Treatment
03.00 p.m.	A. Stack (Limerick, IE) Is there any "J-shaped" curve for serum uric acid?
03.20 p.m	C. Borghi (Bologna, IT) Hyperuricemia and cardiometabolic disease: the role of renal impairment
03.40 p.m.	A. D. Struthers (Dundee, UK) The treatment of asimptomatic hyperuricemia: who, when and why
04.00 p.m.	<b>L. G. Sanchez-Lozada</b> (Mexico City, MX) The non-pharmacologic approach to hyperuricemia. Solutions beyond diet
04.20 p.m.	J. T. Kielstein (Braunschweig, DE) How to investigate the cardiovascular and renal effects of urate-lowering drugs?
04.40 p.m.	General discussion
05.10 p.m.	Closing Remarks and end of the Symposium

# INTERNATIONAL SYMPOSIUM ON:

# URIC ACID AND CARDIOMETABOLIC DISEASE: FROM BENCH TO BEDSIDE



# GENERAL INFORMATION

### **M**EETING VENUE

The venue for the Meeting is Salone del Podestà, Palazzo Re Enzo - Piazza del Nettuno, 1 - Bologna

### SECRETARIAT DESK DURING THE MEETING

The secretariat desk is open at the following times:

Tuesday, November 13th, from 08.00 a.m. to 06.00 p.m.

Wednesday, November 14th, from 08.00 a.m. to 05.30 p.m.

### **O**FFICIAL LANGUAGE

The official language of the Meeting is English.

### REGISTRATION

The Meeting is free to attend. The registration link is available on the website www.iec-srl.it until November 8th. Onsite registrations can be accepted.

### **TECHNICAL FACILITIES SPEAKERS**

Facilities are available for computer presentations and overhead projections.

A slide center with PC (Powerpoint for Windows) is available for check and preview of presentations. It is essential that speakers take their presentations to the slide center at least one hour before the session starts.

The slide center is open at the following times:

Tuesday, November 13th, from 08.00 a.m. to 06.00 p.m.

Wednesday, November 14th, from 08.00 a.m. to 05.30 p.m.

### **LUNCHES AND COFFEE BREAKS**

Lunches and coffee breaks are served in the Congress area.

### **A**BSTRACTS BOOK

Participants can get the abstract book at the Symposium.

### **CERTIFICATE OF ATTENDANCE**

The certificate of attendance is available, on request, at the end of the Meeting at the secretariat desk.

### **CME CREDITS**

EACCME and EBAC Credits have been obtained for physicians for the following disciplines: Cardiology, Internal Medicine, Metabolic and Diabetes Diseases, Nephrology, Rheumatology, Endocrinology, Neurology, Clinical Biochemistry, Hygiene.

### ITALIAN CME CREDITS

Provider Italian CME Credits: I&C s.r.l. 5387 (event number 240472)

Number of credits: 4.2

1&C~s.r.l. is responsible for the content, the quality and the ethical honesty of the CME activity.

The meeting is accredited for the following professions: Nurse, Pharmacist, Biologist, Physician (specialties: Cardiology, Internal Medicine, Metabolic and Diabetes Diseases, Nephrology,

Rheumatology, Endocrinology, Neurology, Clinical Biochemistry, Hygiene). The physicians belonging to other specialties will not get the credits.

The attendance to the meeting is partially on sponsor companies invitation.

METHODOLOGY: Residential

COURSE OBJECTIVES: Clinical, Diagnostic, Therapy, Treatment Path

In order to obtain CME credits, it is mandatory for participants to attend 90% of the course (both days) and to complete CME procedures online: learners' feedback form and educational needs form. Instructions are provided on site.

# GENERAL INFORMATION

### **EACCME CREDITS**



The "URIC ACID AND CARDIOMETABOLIC DISEASE: FROM BENCH TO BEDSIDE", Bologna, Italy, 13/11/2018-14/11/2018 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 14 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities. Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

### EACCME® credits

Each participant can only receive the number of credits he/she is entitled to according to his/her actual participation at the event once he/she has completed the feedback form. Cf. criteria 9 and 23 of UEMS 2016.20.

In order to help you issue individual certificates to each participants, please find below the breakdown of ECMEC®s per day:

13.11.2018 - 7.00

14.11.2018 - 7.00

The EACCME® awards ECMEC®s on the basis of 1 ECMEC® for one hour of CME with a maximum of 8 ECMEC®s per day. Cf. Chapter X of UEMS 2016.20.

### **EBAC CREDITS**



### EBAC

The event "URIC ACID AND CARDIOMETABOLIC DISEASE: FROM BENCH TO BEDSIDE" (Ref. 00004467), is accredited by the European Board for Accreditation in Cardiology for 13 CME credit hour(s) (Day #1: 7 CME credit(s) - Day #2: 6 CME credit(s)).

Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

# **FACULTY**

### Enrico Agabiti-Rosei

Department of Clinical and Experimental Sciences University of Brescia Spedali Civili di Brescia Brescia (Italy)

### Michael H. Alderman

Distinguished University Professor Emeritus Departments of Medicine and Population Health Albert Einstein College of Medicine Bronx, New York-NY (USA)

### Giuseppe Ambrosio

Department of Cardiology University of Perugia S. Maria della Misericordia Hospital Perugia (Italy)

### Ettore Ambrosioni

Internal Medicine University of Bologna (Former Professor) Bologna (Italy)

### Mariano Andrés

Department of Rheumatology General University Hospital of Alicante Miguel Hernández University Alicante (Spain)

### Claudio Borghi

Department of Medical and Surgical Sciences (DIMEC)
Department of Internal Medicine
Alma Mater Studiorum University of Bologna
St. Orsola-Malpighi University Hospital
Bologna (Italy)

### Michel Burnier

Nephrology and Hypertension Department of Medicine Vaud University Hospital Center Lausanne (Switzerland)

### Renata Cifkova

Center of Cardiovascular Prevention First Faculty of Medicine Charles University, Thomayer Hospital Prague (Czech Republic)

### Jesse Dawson

Institute of Cardiovascular and Medical Sciences University of Glasgow Queen Elizabeth University Hospital Glasgow (United Kingdom)

### Giovambattista Desideri

Division of Geriatric Medicine University of L'Aquila SS Filippo and Nicola Hospital Avezzano-L'Aquila (Italy)

### Daniel I. Feig

Division of Nephrology, Pediatrics University of Alabama Birmingham-AL (USA)

### Claudio Ferri

Division of Internal Medicine and Nephrology School of Internal Medicine University of L'Aquila San Salvatore Hospital Coppito - L'Aquila (Italy)

### Francesco M. Galassi

College of Humanities, Arts and Social Sciences Flinders University Adelaide - SA (Australia)

### **Jacob George**

Cardiovascular Medicine & Therapeutics TASC Research and Development Office Tayside Medical Sciences Centre University of Dundee, Ninewells Hospital Dundee (United Kingdom)

### **Terence Gibson**

Department Acute Medicine Guy's and St Thomas' NHS Foundation Trust London (United Kingdom)

### Michael M. Givertz

Cardiovascular Division Brigham and Women's Hospital Harvard Medical School Boston-MA (USA)

### Guido Grassi

Internal Medicine, School of Medicine and Surgery University of Milano-Bicocca St. Gerardo Hospital, Monza Milan (Italy)

### Richard J. Johnson

Division of Renal Diseases and Hypertension University of Colorado Anschutz Medical Campus Aurora-CO (USA)

### **Duk-Hee Kang**

Department of Internal Medicine Division of Nephrology Ewha Women's University College of Medicine Seoul (Korea)

### Jan T. Kielstein

Nephrology and Rheumatology Department Academic Teaching Hospital Braunschweig Braunschweig (Germany)

### Masanari Kuwabara

Department of Cardiology Toranomon Hospital Tokyo (Japan)

### **Empar Lurbe**

Pediatrics Department University of Valencia, Clinical Hospital of Valencia Valencia (Spain)

### Giuseppe Mancia

University of Milano-Bicocca Milan (Italy)

### Athanasios J. Manolis

Department of Cardiology "Asklepeion" General Hospital Athens (Greece)

### Stefano Masi

Department of Clinical and Experimental Medicine University of Pisa Pisa (Italy)

### Tony R. Merriman

Biochemistry Department School of Medical Sciences University of Otago Dunedin (New Zealand)

### Maria Lorenza Muiesan

Internal Medicine, School of Emergency Medicine University of Brescia Department of Medicine – Spedali Civili of Brescia Brescia (Italy)

### **Krzysztof Narkiewicz**

Department of Hypertension and Diabetology Medical University of Gdansk Gdansk (Poland)

### Peter M. Nilsson

Lund University
Department Clinical Sciences
Skane University Hospital
Malmo (Sweden)

### Paolo Palatini

Department of Medicine University of Padua Padua (Italy)

### Roberto Pontremoli

Department of Internal Medicine and Medical Specialties University of Genoa Genoa (Italy)

### Leonardo Punzi

Rheumatology Unit Department of Medicine Medical School University of Padua Padua (Italy)

### Josep Redon

Department of Internal Medicine University of Valencia, Clinical Hospital of Valencia Valencia (Spain)

### Dietrich Rotenbacher

Institute of Epidemiology and Medical Biometry Ulm University Ulm (Germany)

### L. Gabriela Sanchez-Lozada

Department of Nephrology National Institute of Cardiology Ignacio Chávez Mexico City (Mexico)

### Lieke Scheepers

Biometrics, Early Clinical Development IMED Biotech Unit, AstraZeneca Gothenburg (Sweden)

### **Austin Stack**

Department of Nephrology University Hospital Limerick & Graduate Entry Medical School University of Limerick Limerick (Ireland)

### Allan D. Struthers

Cardiovascular Medicine Medical Research Institute Division of Molecular and Clinical Medicine University of Dundee Dundee (United Kingdom)

### Stefano Taddei

Department of Internal Medicine University of Pisa Pisa (Italy)

### Konstantinos Tsioufis

First Cardiology Clinic, Medical School National and Kapodistrian University of Athens Hippokration Hospital Athens (Greece)

### **Agostino Virdis**

Department of Clinical and Experimental Medicine University of Pisa Pisa (Italy)

### Sasiwarang Goya Wannamethee

Primary Care and Population Health UCL Medical School London (United Kingdom)

# **NOTES**

# **NOTES**

